 | Up a level |
2020
Abruzzo, Lynne, Herling, Carmen, Coombes, Kevin, Benner, Axel, Bloehdorn, Johannes, Barron, Lynn L., Abrams, Zachary, Majewski, Tadeusz, Bondaruk, Jolanta, Bahlo, Jasmin, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan, Czerniak, Bogdan, Oakes, Christopher, Ferrajoli, Alessandra and Keating, Michael (2020). Gene expression signatures predict time-to-progression after front-line chemoimmunotherapy for CLL. Leuk. Lymphoma, 61. S. 7 - 9. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403
2018
Hallek, Michael, Cheson, Bruce D., Catovsky, Daniel, Caligaris-Cappio, Federico, Dighiero, Guillermo, Doehner, Hartmut, Hillmen, Peter, Keating, Michael, Montserrat, Emili, Chiorazzi, Nicholas, Stilgenbauer, Stephan, Rai, Kanti R., Byrd, John C., Eichhorst, Barbara, O'Brien, Susan, Robak, Tadeusz, Seymour, John F. and Kipps, Thomas J. (2018). iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 131 (25). S. 2745 - 2761. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
2015
Stilgenbauer, Stephan, Jones, Jeffrey A., Coutre, Steven, Mato, Anthony R., Hillmen, Peter, Tam, Constantine, Osterborg, Anders, Siddiqi, Tanya, Thirman, Michael J., Furman, Richard R., Ilhan, Osman, Keating, Michael, Call, Timothy G., Brown, Jennifer R., Li, Yunfeng, Eckert, Karl, Chang, Betty Y., James, Danelle F., Chu, Alvina D., Hallek, Michael and O'Brien, Susan (2015). Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
2014
O'Brien, Susan, Jones, Jeffrey A., Coutre, Steven, Mato, Anthony R., Hillmen, Peter, Tam, Constantine, Osterborg, Anders, Siddiqi, Tanya, Thirman, Michael J., Furman, Richard R., Ilhan, Osman, Keating, Michael, Call, Timothy G., Brown, Jennifer R., Stevens-Brogan, Michelle, Li, Yunfeng, Fardis, Maria, Clow, Fong, James, Danelle F., Chu, Alvina D., Hallek, Michael and Stilgenbauer, Stephan (2014). Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE (TM)-17 Trial. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020